Decrease in GTP-sensitive high affinity agonist binding of muscarinic acetylcholine receptors in autopsied brains of dementia with Lewy bodies and Alzheimer's disease

Journal of the Neurological Sciences

Volumn 223, Issue 2, 2004, Pages 145-148

  Shiozaki, Kazumasa ^a   Iseki, Eizo ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease (AD); Dementia with Lewy bodies (DLB); GTP binding regulatory protein (G protein); GTP sensitive agonist high affinity binding; mAChR; mAChR G protein complex; muscarinic acetylcholine receptor; Muscarinic acetylcholine receptor (mAChR)

Indexed keywords

CARBACHOL; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE; MUSCARINIC RECEPTOR; QUINUCLIDINYL BENZILATE; TRITIUM;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BINDING AFFINITY; BRAIN CORTEX; BRAIN TISSUE; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DEMENTIA; FRONTAL CORTEX; FRONTAL LOBE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEWY BODY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; AUTOPSY; BINDING, COMPETITIVE; BRAIN; CARBACHOL; CHOLINERGIC AGONISTS; FEMALE; GUANOSINE TRIPHOSPHATE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; POSTMORTEM CHANGES; QUINUCLIDINYL BENZILATE; RECEPTORS, MUSCARINIC;

EID: 4444364484     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.05.002     Document Type: Article

References (18)

1. Shiozaki K., Haga T. Effects of magnesium ion on the interaction of atrial muscarinic acetylcholine receptors and GTP-binding regulatory proteins. Biochemistry. 31(43):1992;10634-10642
2. Brown D., Chisholm J.A., Owens J., Pimlott S., Patterson J., Wyper D. Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging. 30(2):2003;296-300
3. Dickson D.W., Davies P., Mayeux R., Crystal H., Horoupian D.S., Thompson A., et al. Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients. Acta Neuropathol. (Berl.). 75(1):1987;8-15
4. Liberini P., Valerio A., Memo M., Spano P.F. Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease? Trends Pharmacol. Sci. 17(4):1996;155-160
5. Levy R., Eagger S., Griffiths M., Perry E., Honavar M., Dean A., et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet. 343(8890):1994;176
6. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 47(5):1996;1113-1124
7. Kosaka K. Diffuse Lewy body disease. Intern. Med. 37(1):1998;6-10
8. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41(4):1991;479-486
9. Shiozaki K., Iseki E., Uchiyama H., Watanabe Y., Haga T., Kameyama K., et al. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 67(2):1999;209-213
10. Araujo D.M., Lapchak P.A., Robitaille Y., Gauthier S., Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J. Neurochem. 50(6):1988;1914-1923
11. Nordberg A., Alafuzoff I., Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 31(1):1992;103-111
12. Perry E.K., Smith C.J., Court J.A., Perry R.H. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J. Neural Transm., Parkinson's Dis. Dement. Sect. 2(3):1990;149-158
13. Flynn D.D., Ferrari-DiLeo G., Mash D.C., Levey A.I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. 64(4):1995;1888-1891
14. Ferrari-DiLeo G., Mash D.C., Flynn D.D. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol. Chem. Neuropathol. 24(1):1995;69-91
15. Warpman U., Alafuzoff I., Nordberg A. Coupling of muscarinic receptors to GTP proteins in postmortem human brain-alterations in Alzheimer's disease. Neurosci. Lett. 150(1):1993;39-43
16. Ladner C.J., Celesia G.G., Magnuson D.J., Lee J.M. Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 54(6):1995;783-789
17. Ladner C.J., Lee J.M. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations. Exp. Neurol. 158(2):1999;451-458
18. Flynn D.D., Weinstein D.A., Mash D.C. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann. Neurol. 29(3):1991;256-262